Description and Brand Names
Drug information provided by: IBM Micromedex
US Brand Name
- Sarclisa
Descriptions
Isatuximab-irfc injection is used in combination with pomalidomide and dexamethasone to treat multiple myeloma (a type of bone marrow cancer) in patients who have received at least 2 previous treatments (eg, lenalinomide and a proteasome inhibitor).
Isatuximab-irfc injection is also used in combination with carfilzomib and dexamethasone to treat relapsed (cancer that has come back) or refractory (cancer that did not respond to treatment) multiple myeloma in patients who have received 1 to 3 previous treatments that did not work well.
Isatuximab-irfc injection is an antineoplastic agent (cancer medicine) that interferes with the growth of cancer cells, which are eventually destroyed by the body.
This medicine is to be given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: Feb. 01, 2022
Copyright © 2022 IBM Watson Health. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.